REHOVOT, Israel, Jan. 23,
2024 /PRNewswire/ -- Biomica Ltd., a
clinical-stage biopharmaceutical company developing innovative
microbiome-based therapeutics and a subsidiary of Evogene
Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced its CEO, Dr. Elran
Haber, will participate in the 8th Annual Microbiome Movement Drug
Development Summit Europe in Barcelona,
Spain, from January 30 to February 1,
2024.
The summit gathers leading drug developers and microbiome
experts to discuss microbiome functionality, translation, clinical
development, biomarker discovery, and manufacturing scale-up. Dr.
Haber will join two industry panel discussions: "The Future of
Microbiome Therapeutics as Co-therapies: Investment &
Development Considerations" on January 30,
2024, at 3:30pm GMT, and
"Microbiome Business Pioneers: An Evaluation of Microbiome Industry
Verticals & Future Perspectives" on February 1, 2024, at 4:15pm GMT.
Dr. Haber will be available for one-on-one meetings at the
conference, and interested parties can contact the investor or
public relations team.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing
innovative microbiome-based therapeutics utilizing PRISM system, a
proprietary computational platform powered by Evogene's
MicroBoost AI tech-engine. licensed from Evogene. Biomica
aims to identify and characterize disease-related microbiome
entities and to develop novel therapeutics based on these
understandings. The company is focused on the development of
therapies for antibiotic resistant bacteria, immuno-oncology, and
microbiome-related gastrointestinal (GI) disorders. Biomica is a
subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN).
For more information, please visit www.biomicamed.com
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass AI and
GeneRator AI – leveraging Big Data and Artificial
Intelligence and incorporating deep multidisciplinary understanding
in life sciences. Each tech-engine is focused on the discovery
and development of products based on one of the following core
components: microbes (MicroBoost AI), small molecules
(ChemPass AI), and genetic elements (GeneRator
AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com
Contacts
Rachel Pomerantz
Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo -
https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/biomica-ceo-set-to-engage-in-panel-discussion-at-8th-annual-european-microbiome-movement-summit-302041863.html
SOURCE Biomica Ltd.